UltraSight Overview
UltraSight’s mission is to make diagnostic imaging more accessible by empowering medical professionals to successfully acquire timely and accurate cardiac ultrasound images anywhere. UltraSight's AI-driven software offers real-time guidance, making cardiac ultrasound accessible and efficient, which may lead to quicker diagnoses and improved patient care. In 2022, UltraSight won the Bristol Myers Squibb Improving Cardiovascular Disease Outcomes Challenge as the most “innovative cardiac technology.” Additionally, the company was awarded a patent for its real-time guidance solution for ultrasound devices. UltraSight’s software has FDA 510(k) Clearance, is UKCA and CE Marked, and has Israeli AMAR Clearance to assist medical professionals in performing cardiac ultrasound scans.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
UltraSight collaborates with Mayo Clinic to advance next generation cardiac care with AI
UltraSight, a digital health company specializing in cardiac imaging with artificial intelligence, is partnering with Mayo Clinic to develop algorithms for analyzing and interpreting cardiac ultrasound images. The collaboration aims to create a new solution and decision support to help healthcare providers make more informed diagnoses and treatment decisions using point-of-care ultrasound devices. Mayo Clinic is now an investor in UltraSight and will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
PartnersInvestment
growth-positive
Korean Firm Bringing Israeli Ultrasound Software To Local Market
Israeli startup UltraSight has partnered with South Korean medical device manufacturer Selvas Healthcare to introduce its AI-powered cardiac ultrasound software into the Asian market. The software provides real-time support for cardiac ultrasound imagery, improving diagnoses and patient care. This partnership marks UltraSights first step into the Korean market and includes securing approvals for distribution in the country. Selvas will have exclusive distribution rights to UltraSights technology.
PartnersExpand
growth-positive
FDA Grants Clearance for UltraSight's AI-Powered Cardiac Ultrasound Technology
UltraSight, a digital health company, has received FDA clearance for its AI-powered ultrasound guidance technology. The software assists medical professionals without sonography experience in acquiring cardiac ultrasound images at the point of care in multiple settings. This will allow for more widespread detection of heart disease and easier access to cardiac monitoring for patients. UltraSights solution will enable hospital staff to advance patient triage and treatment with increased efficiency and clinical confidence. It can also increase access to care for chronic heart disease patients by bringing cardiac ultrasound into local communities.
InvestmentExpand
growth-positive
UltraSight and EchoNous Partner to Enable More Accessible Cardiac Ultrasound for Patients
UltraSight, a digital health company specializing in cardiac imaging through artificial intelligence, has announced a partnership with EchoNous, a point-of-care ultrasound innovator. The partnership aims to enable more healthcare professionals to perform cardiac ultrasound, thereby increasing patient access to cardiac care. UltraSights real-time AI guidance software will be integrated with EchoNous KOSMOS handheld ultrasound device. The goal is to enable chronic cardiac patient monitoring to be done closer to patients. The partnership was announced at ASE 2023.
Partners
growth-positive
UltraSight Granted Patent for Real-Time Guidance Ultrasound Technology
UltraSight, an Israeli-based digital health pioneer, has been granted a patent for its real-time guidance technology for ultrasound devices. The technology aims to simplify cardiac ultrasound and allow medical professionals with no prior sonography experience to accurately perform echocardiographic examinations. UltraSights guidance software is currently under FDA review. The company has also partnered with The Weizmann Institute of Science and NYU Langone School of Medicine. The patent was granted by the U.S. Patent and Trademark Office (USPTO).
PartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $15.2M |
| Last funding | Undisclosed |
| Stage | B |
| Rounds | 4 |
| Investors | 4 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | ultrasight.com |
Locations
Pinhas Sapir St 8, Ness Ziona, Israel
1 Broadway, Cambridge, MA 02142, USA
Photos & Videos
1 item(s)
